Interactions of Hormone Replacement Therapy, Body Weight, and Bilateral Oophorectomy in Breast Cancer Risk

Purpose: To examine potential modifying effects of body weight and bilateral oophorectomy on the association of hormone replacement therapy (HRT) with risk of breast cancer, overall and by subtypes according to status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2) among postmenopausal women. Experimental Design: This analysis included 2,510 postmenopausal white women recruited in the Nashville Breast Health Study, a population-based case–control study of breast cancer. Multivariable logistic regression was used to estimate ORs and 95% confidence intervals (CI) for associations between HRT use and risk of breast cancer overall and by subtypes, adjusted for age and education. Results: Among women with natural menopause and body mass index (BMI) < 25 kg/m2, ever-use of HRT was associated with increased breast cancer risk (OR, 1.95; 95% CI, 1.32–2.88). Risk was elevated with duration of HRT use (P for trend = 0.002). Similar association patterns were found for ER+, ER+PR+, and luminal A cancer subtypes but not ER−, ER−PR−, and triple-negative cancer. In contrast, ever-HRT use in overweight women (BMI ≥ 25 kg/m2) showed no association with risk of breast cancer overall or by subtypes; interaction tests for modifying effect of BMI were statistically significant. Ever-HRT use was associated with decreased breast cancer risk (OR, 0.70; 95% CI, 0.38–1.31) among women with prior bilateral oophorectomy but elevated risk (OR, 1.45; 95% CI, 0.92–2.29) among those with hysterectomy without bilateral oophorectomy (P for interaction = 0.057). Similar associations were seen for virtually all breast cancer subtypes, although interaction tests were statistically significant for ER+ and luminal A only. Conclusion: Body weight and bilateral oophorectomy modify associations between HRT use and breast cancer risk, especially the risk of hormone receptor–positive tumors. Clin Cancer Res; 20(5); 1169–78. ©2014 AACR.

[1]  I. Gram,et al.  Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study , 2012, Breast Cancer Research.

[2]  G. Anderson,et al.  Changing concepts: Menopausal hormone therapy and breast cancer. , 2012, Journal of the National Cancer Institute.

[3]  L. Ford,et al.  Paradoxical Clinical Effect of Estrogen on Breast Cancer Risk: A “New” Biology of Estrogen-induced Apoptosis , 2011, Cancer Prevention Research.

[4]  J. Manson,et al.  Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. , 2011, JAMA.

[5]  R. Prentice,et al.  Body Size, Physical Activity, and Risk of Triple-Negative and Estrogen Receptor–Positive Breast Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[6]  A. Thind,et al.  Validity of self-reports of breast cancer treatment in low-income, medically underserved women with breast cancer , 2010, Breast Cancer Research and Treatment.

[7]  J. Reis-Filho,et al.  Histological and molecular types of breast cancer: is there a unifying taxonomy? , 2009, Nature Reviews Clinical Oncology.

[8]  C. Parise,et al.  Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999–2004 , 2009, The breast journal.

[9]  W. Mack,et al.  Influence of age and obesity on serum estradiol, estrone, and sex hormone binding globulin concentrations following oral estrogen administration in postmenopausal women. , 2009, The Journal of clinical endocrinology and metabolism.

[10]  A. Onitilo,et al.  Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival , 2009, Clinical Medicine & Research.

[11]  V. Jordan,et al.  Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? , 2009, Breast Cancer Research.

[12]  M. Pike,et al.  American Journal of Epidemiology Original Contribution Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status the Multiethnic Cohort Study , 2022 .

[13]  D. English,et al.  Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition , 2009, Breast Cancer Research and Treatment.

[14]  A. Wolk,et al.  Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status—A meta‐analysis , 2009, International journal of cancer.

[15]  J. Klijn,et al.  Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers , 2008, Journal of the National Cancer Institute.

[16]  E W Steyerberg,et al.  Polytomous logistic regression analysis could be applied more often in diagnostic research. , 2008, Journal of clinical epidemiology.

[17]  P. Hall,et al.  Risk Factors for Hormone Receptor-Defined Breast Cancer in Postmenopausal Women , 2006, Cancer Epidemiology Biomarkers & Prevention.

[18]  V. Beral,et al.  Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. , 2006, The Lancet. Oncology.

[19]  M. Pike,et al.  Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies , 2006, Breast Cancer Research.

[20]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[21]  K. Malone,et al.  Interactions between Body Mass Index and Hormone Therapy and Postmenopausal Breast Cancer Risk (United States) , 2006, Cancer Causes & Control.

[22]  J. Yager,et al.  Estrogen carcinogenesis in breast cancer. , 2006, The New England journal of medicine.

[23]  Tianyu Li,et al.  Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. , 2005, Journal of the National Cancer Institute.

[24]  D. Jeffe,et al.  Self-report by elderly breast cancer patients was an acceptable alternative to surveillance, epidemiology, and end results (SEER) abstract data. , 2005, Journal of clinical epidemiology.

[25]  J. Chang-Claude,et al.  Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. , 2005, Endocrine-related cancer.

[26]  Zhao Chen,et al.  Ethnicity and breast cancer: factors influencing differences in incidence and outcome. , 2005, Journal of the National Cancer Institute.

[27]  O. Olopade,et al.  Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  G. Giles,et al.  Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. García-Closas,et al.  Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[30]  F. Clavel-Chapelon,et al.  Body size and breast cancer risk: Findings from the European prospective investigation into cancer and nutrition (EPIC) , 2004, International journal of cancer.

[31]  Graham A Colditz,et al.  Risk factors for breast cancer according to estrogen and progesterone receptor status. , 2004, Journal of the National Cancer Institute.

[32]  A. Howell,et al.  Central obesity and breast cancer risk: a systematic review , 2003, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[33]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P. Porter,et al.  Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. , 2003, JAMA.

[35]  Emily White,et al.  Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States) , 2002, Cancer Causes & Control.

[36]  M. Pike,et al.  Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J R Marshall,et al.  Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. , 2000, American journal of epidemiology.

[39]  B Rosner,et al.  Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses' Health Study. , 1999, American journal of epidemiology.

[40]  T. Sellers,et al.  Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. , 1999, JAMA.

[41]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[42]  L. Brinton.  Hormone replacement therapy and risk for breast cancer. , 1997, Endocrinology and metabolism clinics of North America.

[43]  J. Marsden.  Hormone-replacement therapy and breast cancer. , 2002, The Lancet. Oncology.

[44]  J. Manson,et al.  Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the Nurses' Health Study (United States) , 1995, Cancer Causes & Control.

[45]  M. Baum.  Hormone replacement therapy and breast cancer , 1994, The Lancet.

[46]  V. Beral,et al.  Breast cancer risk in relation to the interval between menopause and starting hormone therapy. , 2011, Journal of the National Cancer Institute.

[47]  A. Howell,et al.  Energy restriction for breast cancer prevention. , 2009, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[48]  S. Hankinson,et al.  and Breast Cancer Risk , 2005 .

[49]  A. Trentham-Dietz,et al.  American Journal of Epidemiology Practice of Epidemiology Bilateral Oophorectomy in Relation to Risk of Postmenopausal Breast Cancer: Confounding by Nonmalignant Indications for Surgery? , 2022 .